Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) Director Jason David Sawyer purchased 240,000 shares of the stock in a transaction that occurred on Wednesday, July 22nd. The stock was bought at an average cost of $0.23 per share, with a total value of $55,200.00. Following the acquisition, the director owned 240,000 shares of the company’s stock, valued at $55,200. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
Greenland Mines Ltd. Common Stock Stock Performance
NASDAQ:GRML opened at $0.20 on Wednesday. The company has a market cap of $27.46 million, a price-to-earnings ratio of -0.62 and a beta of 7.05. The stock’s fifty day moving average price is $0.27 and its two-hundred day moving average price is $0.37. Greenland Mines Ltd. Common Stock has a 52-week low of $0.16 and a 52-week high of $1.12.
Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last released its earnings results on Wednesday, May 20th. The company reported ($0.15) earnings per share for the quarter.
Institutional Investors Weigh In On Greenland Mines Ltd. Common Stock
Wall Street Analyst Weigh In
A number of research firms have issued reports on GRML. Weiss Ratings upgraded shares of Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Wall Street Zen raised shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a research note on Saturday, May 2nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Greenland Mines Ltd. Common Stock presently has a consensus rating of “Sell”.
View Our Latest Report on Greenland Mines Ltd. Common Stock
Greenland Mines Ltd. Common Stock Company Profile
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Recommended Stories
- Five stocks we like better than Greenland Mines Ltd. Common Stock
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Greenland Mines Ltd. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenland Mines Ltd. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
